- Meeting abstract
- Open Access
Use of prostacyclin in pulmonary hypertension
© Current Science Ltd 1998
- Published: 1 March 1998
- Pulmonary Artery
- Pulmonary Hypertension
- Ventricular Function
The use of drugs such as epoprostenol which dilate the pulmonary vessels is indicated in patients with primary pulmonary hypertension in order to improve their clinical status before being transplanted.
We describe our experience in six patients with primary pulmonary hypertension who received prostacyclin and underwent lung transplantation sometime later.
Six patients aged between 19 and 50 years old (2 female, 4 male). Base diagnosis was primary pulmonary hypertension. In all of them a haemodynamic study with Swan-Ganz catheter was performed. Patients were treated initially with acenocumarol and diltiazem. If they presented auricular fibrilation or low right ventricular function, digoxin was associated. If the end telediastolic right ventricular pressure was increased, dicumarinic was associated. If the right ventricular function became worse, prostacyclin was added to the treatment.
Dose of prostacyclin: 4–6 ng/kg per min
Time of waiting before lung transplantation: 25 days to 6 months
Clinical improvement of right ventricular function: 5 patients
Dysnea after moderate efforts: 3 patients
Improvement of pulmonary artery pressure: 6 patients
Prostacyclin is an usefull treatment of pulmonary hypertension to improve the clinical status and the haemodynamic parameters in these patients and it helps until lung transplantation can be performed.